Asthma Clinical Trial
Official title:
Assessment of Mast Cell Activation Diagnostic Test in Patients With Allergic Disease
Verified date | March 2020 |
Source | Hong Kong Sanatorium & Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Activation of mast cells in the immune system is known to cause allergic reactions sometimes with severe systemic symptoms. The investigators have recently developed a blood-based mast cell activation diagnostic test in which levels of functional activation in-vitro in primary cultured mast cells generated from the peripheral blood of single individuals can be assessed. It is the hypothesis that the test can be used to predict the potential state of in-vivo mast cell activation in any individual based on the functional activation profiles exhibited by their cultured mast cells. The investigators now wish to translate their in-vitro findings in a pilot study to disease groups where mast cell activation is expected to be high. These include highly allergic individuals; those with chronic idiopathic urticaria; those with mastocytosis; and those with the mast cell activation syndrome. Furthermore, they will use the functional genomics approach to identify gene expression biomarkers that are correlated with such diseases. The results will be compared with data that have been collected from a cohort of healthy control blood donors.
Status | Completed |
Enrollment | 19 |
Est. completion date | December 1, 2019 |
Est. primary completion date | December 1, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: Any patients with the above diagnoses - Exclusion Criteria: Children < 18 years old; those who are unwilling or unable to donate blood; pregnant mothers. - |
Country | Name | City | State |
---|---|---|---|
Hong Kong | Hong Kong Sanatorium & Hospital | Hong Kong |
Lead Sponsor | Collaborator |
---|---|
Hong Kong Sanatorium & Hospital | Chinese University of Hong Kong, Stanford University |
Hong Kong,
Tam IYS, Ng CW, Tam SY, Lau HYA. Novel six-week protocol for generating functional human connective tissue-type (MC(TC)) mast cells from buffy coats. Inflamm Res. 2017 Jan;66(1):25-37. doi: 10.1007/s00011-016-0989-z. Epub 2016 Sep 15. Erratum in: Inflamm Res. 2017 Nov 13;:. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Mast Cell Activation Test Results for Validation Group | Mast Cell Activation Test results of high/low level of house dust mite sensitivity by using normal donor cultured mast cells for validation. | Mast cells studied after 9 weeks in culture | |
Primary | Evaluation of Patient's Serum for Autoreactivity on Normal Average Responder Mast Cell Activation | Patient's serum was incubated with mast cells derived from normal donors for detection of mast cell activation as evidenced by histamine release. | Mast cells studied after 9 weeks in culture | |
Primary | Percentage Histamine Release by Normal Average Responder Mast Cells + Patient's Serum to Assess Autoreactivity | percentage of total histamine release by normal average responder mast cells that had been activated with patient's serum | Mast cells studied after 9 weeks in culture | |
Primary | Percentage Histamine Release by Patient's Mast Cells + Immunoglobulin E (IgE)/Anti-IgE | percentage of total histamine release by patient's mast cells that had been activated with anti-IgE | Mast cells studied after 9 weeks in culture | |
Primary | Percentage of Histamine Release by Patient's Mast Cells + Patient's Serum + Allergen | Percentage of total histamine release when patient's mast cells were activated with patient's own serum and Der p2. Each patient's results are reported individually. | Mast cells studied after 9 weeks in culture | |
Primary | Cell Yield Per 100ml Blood | Cell yield of patient's mast cell culture after 9 weeks in culture as an index of cell growth and differentiation. | Mast cells studied after 9 weeks in culture |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|